Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

US Revenue

US Revenue % Chg.

US Revenue Common Size

Europe Revenue

Europe Revenue % Chg.

Europe Revenue Common Size

Japan Revenue

Japan Revenue % Chg.

Japan Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

CABOMETYX Revenue

CABOMETYX Revenue % Chg.

CABOMETYX Revenue Common Size

COMETRIQ Revenue

COMETRIQ Revenue % Chg.

COMETRIQ Revenue Common Size

Total Product Revenue

Total Product Revenue % Chg.

Total Product Revenue Common Size

License Revenue

License Revenue % Chg.

License Revenue Common Size

Collaboration Services Revenue

Collaboration Services Revenue % Chg.

Collaboration Services Revenue Common Size

Total Collaboration Revenue

Total Collaboration Revenue % Chg.

Total Collaboration Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	LTM	Dec '24	Dec '23
CABOMETYX Revenue	2,081.5	1,798.2	1,614.9
COMETRIQ Revenue	10	11.2	13.9
Total Product Revenue	2,091.5	1,809.4	1,628.9
License Revenue	197.4	349.2	178.6
Collaboration Services Revenue	-0.6	10.1	22.7
Total Collaboration Revenue	196.8	359.3	201.3
Total Revenue	2,288.2	2,168.7	1,830.2

Revenue by Geography	LTM	Dec '24	Dec '23
US Revenue	2,107.5	1,823	1,645.7
Europe Revenue	156	318.6	145
Japan Revenue	24.7	27.1	39.5
Total Revenue by Geography	2,288.2	2,168.7	1,830.2